A new study suggests that how certain immune cells respond to Mavenclad (cladribine) may help explain why the treatment works well for some people with multiple sclerosis (MS), but less so for others. The researchers found that regulatory T-cells, or Tregs — immune cells that normally help keep inflammation in check — are relatively resistant […]
The post New study connects immune cell behavior to Mavenclad response in MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com